<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Research | Khalid</title>
    <link rel="stylesheet" href="style.css">
</head>

<body>

<a class="floating-whatsapp" href="https://wa.me/971553741880" target="_blank">WhatsApp</a>

<header>
    <h1>Research</h1>
    <nav>
        <a href="index.html">Home</a>
        <a href="research.html">Research</a>
        <a href="projects.html">Projects</a>
        <a href="updates.html">Updates</a>
        <a href="cv.html">CV</a>
        <a href="contact.html">Contact</a>
        <a href="research-ar.html" style="float:right;">العربية</a>
    </nav>
</header>

<section>
    <h2>Ongoing Research</h2>

    <!-- Research Item 1 -->
    <div style="
        margin: 25px auto;
        width: 85%;
        background-color: #111;
        border-radius: 12px;
        box-shadow: 0 0 15px #00ff88;
        padding: 15px;
        text-align: center;
    ">
        <h3 style="color: #00ff88; margin-bottom: 10px;">
            Clinical Research: Spravato Treatment for TRD in the UAE (2026)
        </h3>

        <p style="color: #c8ffc8; font-size: 16px;">
            A clinical study conducted in Dubai evaluating the effectiveness of Spravato (Esketamine), 
            an NMDA receptor antagonist, in patients with major depressive disorder or treatment‑resistant 
            depression who did not respond to standard therapies.
        </p>

        <p style="color: #c8ffc8; font-size: 14px;">
            <strong>Location:</strong> Dubai, United Arab Emirates<br>
            <strong>Duration:</strong> January 1, 2026 – March 2026<br>
            <strong>Status:</strong> Ongoing
        </p>

        <a href="spravato-uae-2026.html" 
           style="color:#00ff88; font-weight:bold; text-decoration:underline;">
            View Full Research →
        </a>
    </div>

    <!-- Research Item 2 -->
    <div style="
        margin: 25px auto;
        width: 85%;
        background-color: #111;
        border-radius: 12px;
        box-shadow: 0 0 15px #00ff88;
        padding: 15px;
        text-align: center;
    ">
        <h3 style="color: #00ff88; margin-bottom: 10px;">
            Advanced Pharmacological Treatment of TRD in the UAE (2026–2030)
        </h3>

        <p style="color: #c8ffc8; font-size: 16px;">
            A long-term research initiative examining how the United Arab Emirates utilizes 
            advanced medications to treat treatment-resistant depression (TRD). 
            This study investigates clinical response patterns, therapeutic innovations, 
            and evolving psychiatric models within UAE mental health practice.
        </p>

        <p style="color: #c8ffc8; font-size: 14px;">
            <strong>Region:</strong> United Arab Emirates<br>
            <strong>Research Period:</strong> 2026 – 2030<br>
            <strong>Status:</strong> Ongoing
        </p>

        <a href="trd-uae-2026-2030.html" 
           style="color:#00ff88; font-weight:bold; text-decoration:underline;">
            View Full Research Page →
        </a>
    </div>

</section>

<footer>
    <p>© 2026 Khalid — Neuropsychopharmacology Research & Analysis</p>
</footer>

</body>
</html>
